bioRxiv · 10.64898/2026.04.13.718054
CHARIOT-AAV: Conjugation of diverse vectors to adeno-associated viruses for delivery of large genes
Abstract
Systemic, tissue-specific delivery of large transgenes exceeding the packaging capacity of adeno-associated viruses (AAVs) remains a key translational challenge for molecular therapeutics. Vectors with larger capacities, such as lentiviral vectors (LVVs) and lipid nanoparticles (LNPs), often lack adjustable, tissue-specific tropisms. Here we report CHARIOT-AAV (Crosslinked Hybrid Architectures for Robust, Interchangeable, and Organ-specific Targeting with AAV), a platform where diverse delivery vectors are conjugated to AAVs, thereby achieving tissue-specific tropism of AAVs and expanded cargo capacity. AAV-AAV conjugates packaging split SpCas9 constructs in AAV.CAP-B10 capsids demonstrate a [~]2-fold increase in brain gene editing efficiency over unconjugated AAV cocktails after intravenous injection. In addition to AAV-AAV conjugates, AAV-LVV and AAV-LNP conjugates achieve AAV-guided delivery of genetic payloads to target cells. Furthermore, AAV-LNP conjugates enable systemic delivery of mRNAs to brain endothelial cells. CHARIOT-AAV thus provides a modular platform for systemic, tissue-specific delivery of diverse therapeutics beyond the limits of individual vectors.
Explore related subjects
Keep this discovery
Explore connections, maps & timelines
Nagao, K., Osaki, T., Toyonaga, S., Lee, C. G., Vargas Paniagua, E., Crespin Guerra, E., Machen, S., Beckham, J. L., Sur, M., Anderson, D. G., Macfarlane, R. J., Anikeeva, P.. 2026-04-15. CHARIOT-AAV: Conjugation of diverse vectors to adeno-associated viruses for delivery of large genes. https://doi.org/10.64898/2026.04.13.718054
Cite the original work for its findings. Save a collection to share your selection of sources.